DAVID RICHARDSON: Open Payments
NPI 1356570188 · WILMINGTON, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,921 in 114 payments from 22 companies in 2025. Trend: 2023 $1,816 · 2024 $2,121 · 2025 $1,921
Food & beverage: $1,921
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $305 |
| Novo Nordisk Inc | 15 | $278 |
| AstraZeneca Pharmaceuticals LP | 9 | $188 |
| GlaxoSmithKline, LLC. | 9 | $163 |
| Lilly USA, LLC | 7 | $128 |
| PFIZER INC. | 6 | $121 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $93 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $77 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $70 |
| Phathom Pharmaceuticals, Inc. | 9 | $66 |
Products named: TRELEGY ELLIPTA, QULIPTA, JARDIANCE, Wegovy, UBRELVY, CAPLYTA, FARXIGA, VRAYLAR.
Industry payments across NC — which companies pay providers there.
